Document is current
Any future updates will be listed below
-
Authors
Booka, Eisuke
Imamura, Chiyo K.
Takeuchi, Masashi
Kawakubo, Hirofumi
Takeuchi, Hiroya
Tanigawara, Yusuke
Kitagawa, Yuko
Boku, Narikazu https://orcid.org/0000-0002-1438-707X
- License Information
-
More Information
Article History
Received: 24 December 2021
Accepted: 11 March 2022
First Online: 31 March 2022
Declarations
:
: Chiyo K. Imamura has received research fund from Otsuka Pharmaceutical Co., Ltd. Hiroya Takeuchi has received scholarship endowments from Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Factory Inc, Ono Pharmaceutical Co., Ltd., and Eli Lilly Japan KK. Yusuke Tanigawara has received research funds from Takeda Pharmaceutical Co., Ltd. and Asahi Kasei Pharma Corp.; and consulting fee from Fujimoto Pharmaceutical Co. Yuko Kitagawa has received honoraria from Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Asahi Kasei Pharma Corp., and Otsuka Pharmaceutical Factory Inc, and scholarship endowments from Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Factory Inc, Ono Pharmaceutical Co., Ltd., Asahi Kasei Pharma Corp., Yakult Honsha Co., Ltd., Takeda Pharmaceutical Co., Ltd., Eisai Co., Ltd., Tsumura Co., and Medicon Inc. Narikazu Boku has received honoraria from Taiho Pharmaceutical Co., Ltd. and Bristol-Myers Squibb KK, and research funds from Ono Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Co., Ltd. The other authors declare that they have no conflict of interest.
: All procedures followed were in accordance with the ethical standards of the responsible committees on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent was obtained from all patients for their inclusion in the study.
Free to read: This content has been made available to all.
